Delving into the Latest Updates on Beijing Joinn Biologics Co., Ltd. with Synapse

Overview

Tags

Biosimilar

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Biosimilar	1
Monoclonal antibody	1

Top 5 Target	Count

TNF-α(Tumor necrosis factor α)	1

Primary objective: To evaluate the safety and tolerability of different doses of recombinant human C1 esterase inhibitor for injection in asymptomatic HAE patients; Secondary objective: To evaluate the pharmacokinetics, pharmacodynamic characteristics and immunogenicity of different doses of recombinant human C1 esterase inhibitor for injection in asymptomatic HAE patients.

Start Date-

Sponsor / Collaborator

Beijing Joinn Biologics Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Joinn Biologics Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Joinn Biologics Co., Ltd.

Login to view more data

100 Deals associated with Beijing Joinn Biologics Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Joinn Biologics Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Login to view more data